ATE540695T1 - Verfahren zur modulation von il-13 - Google Patents
Verfahren zur modulation von il-13Info
- Publication number
- ATE540695T1 ATE540695T1 AT02749560T AT02749560T ATE540695T1 AT E540695 T1 ATE540695 T1 AT E540695T1 AT 02749560 T AT02749560 T AT 02749560T AT 02749560 T AT02749560 T AT 02749560T AT E540695 T1 ATE540695 T1 AT E540695T1
- Authority
- AT
- Austria
- Prior art keywords
- modulating
- expression
- activity
- modulates
- mammal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29719001P | 2001-06-08 | 2001-06-08 | |
PCT/US2002/017881 WO2002100432A1 (en) | 2001-06-08 | 2002-06-10 | Methods for the modulation of il-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE540695T1 true ATE540695T1 (de) | 2012-01-15 |
Family
ID=23145234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02749560T ATE540695T1 (de) | 2001-06-08 | 2002-06-10 | Verfahren zur modulation von il-13 |
Country Status (4)
Country | Link |
---|---|
US (2) | US20040219149A1 (de) |
EP (1) | EP1401497B1 (de) |
AT (1) | ATE540695T1 (de) |
WO (1) | WO2002100432A1 (de) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003035847A2 (en) * | 2001-10-26 | 2003-05-01 | Centocor, Inc. | Il-13 mutein proteins, antibodies, compositions, methods and uses |
DE602004028007D1 (de) * | 2003-05-14 | 2010-08-19 | Bayer Pharmaceuticals Corp | Interleukin-9 antagonist-muteine und ihre pharmakologischen anwendungsverfahren |
WO2006014953A2 (en) * | 2004-07-28 | 2006-02-09 | Ludwig Institute For Cancer Research | Method for treatment or prophylaxis of a infection using either an antibody which binds to il-9 or an agent which stimulates production of autoantibodies to interleukin-9 |
EP1824886B1 (de) | 2004-11-17 | 2010-12-22 | Amgen Inc. | Vollständige humane monoklonale antikörper gegen il-13 |
CA2688256A1 (en) * | 2007-05-29 | 2008-12-18 | University Of Cincinnati | Methods of modulating inflammation and compositions therefore |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4427660A (en) * | 1982-03-03 | 1984-01-24 | Research Corporation | Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections |
US4703004A (en) * | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
US4761375A (en) * | 1984-05-08 | 1988-08-02 | Genetics Institute, Inc. | Human interleukin-2 cDNA sequence |
US5587302A (en) | 1988-09-19 | 1996-12-24 | Ludwig Institute For Cancer Research | T cell growth factor |
US5208218A (en) * | 1988-09-19 | 1993-05-04 | Ludwig Institute For Cancer Research | T cell growth factor glycoproteins |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5414071A (en) | 1989-05-23 | 1995-05-09 | Genetics Institute, Inc. | Human cytokine IL-9 |
US5580753A (en) | 1989-05-23 | 1996-12-03 | Ludwig Institute For Cancer Research | DNA encoding the human cytokine, interleukin-9 |
IE910916A1 (en) * | 1990-03-23 | 1991-09-25 | Ludwig Inst For Cancer Res Gsf | Method for enhanced growth and proliferation of mast cells |
US5116951A (en) * | 1990-09-19 | 1992-05-26 | Ludwig Institute For Cancer Research | Substantially pure interleukin-9 receptor and uses thereof |
US5132109A (en) * | 1990-10-05 | 1992-07-21 | Ludwig Institute For Cancer Research | Method for inhibiting production of ige and method for enhancing production of igg using interleukin 9 and inhibitors thereof |
US5246701A (en) * | 1990-10-05 | 1993-09-21 | Ludwig Institute For Cancer Research | Method for inhibiting production of IgE by using IL-9 inhibitors |
US5531219A (en) * | 1994-11-04 | 1996-07-02 | Alliance Pharmaceutical Corp. | Use of liquid fluorocarbons to facilitate pulmonary drug delivery |
ES2354360T3 (es) * | 1995-08-24 | 2011-03-14 | Genaera Corporation | Anticuerpo anti-interleucina-9 o anticuerpo del receptor anti-interleucina-9 para el tratamiento de la hiperreactividad bronquial. |
ZA967182B (en) * | 1995-08-24 | 1998-05-25 | Magainin Pharma | Asthma associated factors as targets for treating atopic allergies including asthma and related disorders. |
-
2002
- 2002-06-10 US US10/479,870 patent/US20040219149A1/en not_active Abandoned
- 2002-06-10 AT AT02749560T patent/ATE540695T1/de active
- 2002-06-10 EP EP02749560A patent/EP1401497B1/de not_active Expired - Lifetime
- 2002-06-10 WO PCT/US2002/017881 patent/WO2002100432A1/en not_active Application Discontinuation
-
2008
- 2008-04-25 US US12/109,780 patent/US7919248B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20040219149A1 (en) | 2004-11-04 |
EP1401497A1 (de) | 2004-03-31 |
US20090191191A1 (en) | 2009-07-30 |
US7919248B2 (en) | 2011-04-05 |
WO2002100432A8 (en) | 2003-11-20 |
EP1401497B1 (de) | 2012-01-11 |
EP1401497A4 (de) | 2006-08-16 |
WO2002100432A1 (en) | 2002-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE420947T1 (de) | Gewebeimplant zur wiederherstellung von knorpelgewebe | |
DE60123055D1 (de) | Verfahren zur behandlung von entzündungsbedingten zuständen der augen | |
ATE241358T1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
ATE480253T1 (de) | Verwendung von botulinum toxin zur behandlung von gelenkschmerzen | |
DE60116339D1 (de) | Waschkit sowie verfahren zur kombinierten pflege und reinigung von gewebe | |
ATE419869T1 (de) | Methode zur modulierung eines immunantwortes mit immunstimulierenden sequencen und zusammensetzungen dafür | |
ATE257385T1 (de) | Zusammensetzungen und verfahren zur behandlung des erhöhten augenindruckes | |
DE60118544D1 (de) | Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren | |
ATE466582T1 (de) | 16-phenoxy-lipoxin analoge zur medizinischen verwendung | |
ATE334682T1 (de) | Verfahren zur herstellung von den trans-4-n- butylcyclohexanoicsaüre- und undecanoicsaüreestern von (7-alpha,11-beta)- dimethyl-17 beta -hydroxy-4-estren-3-one und deren medizynische anwendung | |
DE60218922D1 (de) | Verfahren zur Erhöhung der Schwellentoleranz bei empfindlicher Haut | |
DE60130661D1 (de) | Verwendung der 13-cis retinsäure zur behandlung von emphysemen | |
ATE254452T1 (de) | Verfahren zur verbesserung der fertilisierenden aktivität von spermatozoa | |
ATE405282T1 (de) | Verwendung von il-13 inhibitoren zur behandlung von tumoren | |
DE60136748D1 (de) | Verfahren und zusammensetzungen zur behandlung von augenerkrankungen | |
ATE540695T1 (de) | Verfahren zur modulation von il-13 | |
ATE356995T1 (de) | Verfahren zur identifizierung von mitteln zur behandlung von diabetes | |
DE60035693D1 (de) | Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten | |
ATE359816T1 (de) | Verfahren zur prävention und behandlung von infektionen mit dem flavivirus bei tieren | |
DE60015791D1 (de) | Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen | |
ATE452906T1 (de) | Therapeutische zusammenfassungen und verfahren zur modulierung von v3, eine isoform von versican | |
DE60231896D1 (de) | Zusammensetzungen und verfahren zur erhöhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus | |
ATE283920T1 (de) | Verfahren zur immunisierung und behandlung von h. pylori infektion | |
ATE271885T1 (de) | Verfahren zur begasung von geschlossenen systemen | |
ATE291068T1 (de) | Emulgiertes gel |